Patient Characteristics
| Patient Characteristic . | Cyclophosphamide GM-CSF BM Transplant CY/GM/BM . | Cyclophosphamide, ARA-C, and Mitoxantrone G-CSF PBPC Transplant MAC/G/PB . | Cyclophosphamide G-CSF PBPC Transplant CY/G/PB . |
|---|---|---|---|
| Total | 17* | 18-151 | 9-152 |
| Age (range; median) | 29-60; 47 | 35-62; 50 | 36-62; 57 |
| Sex | |||
| Male | 11 | 9 | 3 |
| Female | 6 | 9 | 6 |
| Disease stage-153 | |||
| ECP | 5 | 7 | 3 |
| LCP | 8 | 6 | 4 |
| Accelerated phase | 4 | 5 | 2 |
| Prior therapy | |||
| Hydroxyurea | 14 | 12 | 6 |
| IFN-α | 1 | 0 | 1 |
| Hydroxyurea/IFN-α | 1 | 4 | 1 |
| Multiple-155 | 1 | 2 | 1 |
| Ph positive-164 | |||
| 100% | 15 | 11 | 8 |
| <100% | 2¶ | 6# | 1-160 |
| Negative (BCR/ABL+) | 0 | 1 | 0 |
| WBC at time of mobilization (range; median) | 2.9-84; 7.7 | 2.4-27.2; 9.8 | 2.6-36.1; 4.75 |
| Patient Characteristic . | Cyclophosphamide GM-CSF BM Transplant CY/GM/BM . | Cyclophosphamide, ARA-C, and Mitoxantrone G-CSF PBPC Transplant MAC/G/PB . | Cyclophosphamide G-CSF PBPC Transplant CY/G/PB . |
|---|---|---|---|
| Total | 17* | 18-151 | 9-152 |
| Age (range; median) | 29-60; 47 | 35-62; 50 | 36-62; 57 |
| Sex | |||
| Male | 11 | 9 | 3 |
| Female | 6 | 9 | 6 |
| Disease stage-153 | |||
| ECP | 5 | 7 | 3 |
| LCP | 8 | 6 | 4 |
| Accelerated phase | 4 | 5 | 2 |
| Prior therapy | |||
| Hydroxyurea | 14 | 12 | 6 |
| IFN-α | 1 | 0 | 1 |
| Hydroxyurea/IFN-α | 1 | 4 | 1 |
| Multiple-155 | 1 | 2 | 1 |
| Ph positive-164 | |||
| 100% | 15 | 11 | 8 |
| <100% | 2¶ | 6# | 1-160 |
| Negative (BCR/ABL+) | 0 | 1 | 0 |
| WBC at time of mobilization (range; median) | 2.9-84; 7.7 | 2.4-27.2; 9.8 | 2.6-36.1; 4.75 |
*Two patients not transplanted: one patient insufficient progenitors collected, one patient developed blast crisis immediately after mobilization.
Four patients not transplanted: three patients insufficient progenitors, one patient died from pulmonary infection after mobilization.
Three patients not transplanted: insufficient CD34+cells.
For definition, see Materials and Methods.
One patient IFN-α, hydroxyurea, and busulfan; two patients splenic irradiation and hydroxyurea.
¶Two ECP patients: 35% and 85% Ph-positive metaphases in pretransplantation BM.
#Four ECP patients: 65%, 70%, 90%, and 95% Ph-positive metaphases in pretransplantation BM; two patients previously treated for 2.5 and 3 years with IFN-α with clonal evolution: (1) 35% 46XX t(9,22); 10% 45XX t(9,22) der(7) −12; (2) 15% 46XY t(9,22); 75% 46XY t99,22), add (19).
One ECP CML patient on IFN-α, 65% Ph positive, no clonal evolution.
In most instances, these results are from analysis of a minimum of 20 BM metaphases.